Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind batch-consistency, safety, and immunogenicity study of V116 versus PNEUMOVAX 23 in adults aged 18-49 years
MOH_2022-06-16_011854Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease (4 arms), sponsored by Merck & Co. Primary endpoints: Lot-to-lot consistency of V116 and Safety of V116. Started Jun 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on MOH_2022-06-16_011854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-16_011854.